Name: Cartalax

Alias: EDL Tripeptide, Cartilage Bioregulator Peptide CAS Registry number: N/A Sequence: Glu-Asp-Leu-OH Molecular Formula: C??H??N?O? Molecular Weight: 345.34 Da Purity: ≥99% (by HPLC) Appearance: White lyophilized powder Packing: 20mg*10vials/box Product Group: Cartilage epigenetic regulatory short peptide

Storage Conditions: Store at -20℃ in a dry, dark place; avoid repeated freeze-thaw cycles.

Brief Introduction:

Cartalax is a synthetic EDL tripeptide from Khavinson organ-specific bioregulator series, exclusively for laboratory research. It can cross cell and nuclear membranes to bind chromatin and regulate chondrocyte-related gene expression. It protects articular chondrocytes against oxidative stress and inflammatory factors, boosts synthesis of collagen II and proteoglycans, inhibits matrix metalloproteinases that break down cartilage matrix. It alleviates joint inflammatory edema, slows articular cartilage degradation, restores joint lubrication microenvironment and delays age-related joint degenerative lesions. Widely used in chondrocyte protection, osteoarthritis research, cartilage matrix regeneration and organ-targeted short peptide epigenetic studies.

Main Research Applications:

Chondrocyte protection research: Used in cell and animal models to study chondrocyte anti-apoptosis and oxidative damage relief mechanisms. Cartilage matrix regeneration research: Explore collagen II and proteoglycan upregulation, cartilage degradation inhibition pathways. Osteoarthritis intervention research: Investigate joint inflammation mitigation and degenerative joint lesion delay effects. Joint microenvironment research: Analyze synovial fluid balance and articular lubrication improvement.

Organ bioregulator pharmacology research: Study chromatin-targeted gene regulation characteristics of cartilage-specific short peptides.